Acacia reaches settlement with Mallinckrodt over Exalgo Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
Acacia Research signs patent license agreement with Alcatel-Lucent USA Acacia Research's (ACTG) Labyrinth Optical Technologies subsidiary has entered into a settlement and patent license agreement with Alcatel Lucent (ALU) USA. The agreement resolves litigation that was pending in the U.S. Court for the Central District of California.